AQST - CIK 0001398733
Aquestive Therapeutics, Inc. trades as AQST. In its fiscal 2025 annual report the company posted revenue of $44.55M, down 22.6% from the prior year and net income of -$83.78M. This page tracks Aquestive Therapeutics, Inc. through 641 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years Aquestive Therapeutics, Inc.'s revenue declined from $66.92M to $44.55M, a compound annual decline rate of 5.0%. Net profit margin compressed from -13.4% to -188.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Insider trade | 4 | 2026-05-11 |
| Insider trade | 4 | 2026-05-07 |
The largest companies sharing Aquestive Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Aquestive Therapeutics, Inc. reported revenue of $44.55M for fiscal year 2025, a decrease of 22.6% year over year.
In its latest fiscal year Aquestive Therapeutics, Inc. reported a net loss of $83.78M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.